Artera has achieved a significant milestone in personalized cancer care with its multimodal artificial intelligence platform earning recognition at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The company's oral presentation was selected for Best of ASCO 2025, an honor reserved for studies with the greatest potential to shape the future of cancer care.
Breakthrough in Treatment Personalization
The featured study represents the first validated multimodal artificial intelligence algorithm to identify high-risk, non-metastatic prostate cancer patients who are likely to benefit from adding androgen receptor pathway inhibitors (ARPIs) to standard therapy. Conducted as part of the STAMPEDE trial, the research evaluated the addition of ARPIs—specifically abiraterone acetate plus prednisolone—to standard androgen deprivation therapy and radiation.
The results revealed a striking finding: Artera's model identified that only 25% of high-risk patients derived meaningful benefit from ARPI intensification. This suggests the opportunity to spare up to 75% of this patient cohort from unnecessary toxicities associated with intensive treatment.
"This data helps answer one of the most critical questions in cancer care: which patients will benefit from added treatment, and which will not," said Nick James, MD, PhD, Professor of Prostate and Bladder Cancer Research at The Institute of Cancer Research, London, and Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust.
Addressing Clinical Adoption Challenges
The STAMPEDE trial helped establish ARPIs as the standard of care treatment for high-risk patients, but adoption of ARPIs has been uneven, likely due to concerns over side effects and follow-up care. Artera's AI algorithm addresses this clinical challenge by providing personalized treatment guidance.
"While traditional tests flag patients at risk of poor outcomes, they don't personalize treatment decisions," James explained. "Our collaboration with Artera allows us to uncover patterns invisible to the human eye and optimize treatments like never before. The AI tool allows us to connect beneficial treatments to the patient, while sparing those who may suffer unnecessary side effects, or even premature death, if they receive ARPIs they don't need."
Validation Beyond Initial Treatment
In addition to the oral presentation, Artera will present a poster featuring external validation of its MMAI platform in men who have undergone radical prostatectomy for localized prostate cancer. The study demonstrates that the radical prostatectomy MMAI model serves as an independent prognostic tool for predicting biochemical recurrence and long-term outcomes, even when controlling for clinical risk models.
Scalable Implementation
Artera's solution works with routine pathology and clinical data and does not require extra tissue or complex molecular testing, making it broadly scalable, cost-effective, and faster to implement. The ArteraAI Prostate Test leverages a unique algorithm that assesses digital images from a patient's biopsy and their clinical data, combining this information to determine prognosis and predict whether a patient will benefit from particular therapies.
"We are proud to see Artera's MMAI platform recognized with two abstracts at ASCO, including an oral presentation selected for Best of ASCO," said Timothy Showalter, Chief Medical Officer of Artera. "These studies reinforce our commitment to the rigorous clinical validation of the ArteraAI Prostate Test and our broader MMAI platform."
Clinical Availability and Validation
The ArteraAI Prostate Test has been validated using multiple Phase 3 randomized trials and is clinically available through Artera's CLIA-certified and College of American Pathologists-accredited laboratory in Jacksonville, Florida. The test can be ordered online at artera.ai.
The studies add to the growing body of evidence that Artera's MMAI platform can inform real-time clinical decisions and bring personalized cancer care to broader patient populations, representing a significant advancement in precision oncology for prostate cancer treatment.
